Human Longevity Stock

www.humanlongevity.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $79.98MM

Human Longevity is a genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data.

Register for Details

For more details on financing and valuation for Human Longevity, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Human Longevity.

Register Today

Team

Management Team

Felix Frueh
Chief Scientific Officer
Yaron Turpaz
Chief Information Officer
Williams Biggs
Head, Genomic Sequencing
J. Venter
Co-founder and CEO

Board Members

David Brenner
University of California, San Diego
James Brewer
University of California, San Diego
Delos Cosgrove
Cleveland Clinic
Eric Anderson
Intentional Software

Other companies like Human Longevity in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Human Longevity plans to go public in $1B blank-check deal
The genome sequencing company plans to go public through a merger with Freedom Acquisition I Corp that values the combined company at about $1B.
Xconomy: NeoGenomics Nabs Human Longevity’s Oncology Division for $37M
The genetic testing company NeoGenomics has acquired Human Longevity’s oncology division, which provides next-generation sequencing services. The division
A Deeper Look At Human Longevity Genes
Dr. Nir Barzilai, a Milken Institute Center for the Future on Aging Longevity Innovator, discusses his latest research and what's ahead.
Updated on: Sep 23, 2023